BioSpace News Archive

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced that management will participate in the following upcoming virtual investor conferences:

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter of fiscal 2021, ended July 31, 2020.

Signifier Medical Technologies (“Signifier”), an innovator in the sleep disordered breathing market, is pleased to announce the appointment of Philip Hess as Chief Operating Officer.

Hillrom (NYSE: HRC) today announced that it will present at the virtual 18th Annual Morgan Stanley Global Healthcare Conference on Monday, September 14, 2020 via webcast. John Groetelaars, Hillrom’s president and chief executive officer, is scheduled to present at 12:45 p.m. Eastern Time.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at an upcoming investor conference.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on Tuesday, September 15th.

Sun BioPharma, Inc. (Nasdaq:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced the closing of its previously announced underwritten public offering of 2,545,454 shares of common stock and the same number of warrants to purchase shares of common stock for a price to the public of $4.125 per share and warrant.